bioAffinity Technologies, Inc. (BIAF) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

bioAffinity Technologies, Inc. (BIAF) Healthcare & Pipeline Overview

bioAffinity Technologies, Inc. (BIAF) is a biotechnology company specializing in early cancer diagnostics and targeted therapeutics, with a focus on lung cancer detection through its CyPath lung test. The company operates within the competitive medical diagnostics and research sector, seeking to improve patient outcomes through innovative technologies.

What Is the Investment Thesis for BIAF?

The company's focus on early lung cancer detection addresses a significant unmet need in the healthcare market. The potential for CyPath lung to improve patient outcomes through earlier diagnosis is a key value driver. However, the company's negative profit margin of -280.6% and a small market capitalization of $3.93M indicate substantial financial risks. Growth catalysts include potential FDA approval for CyPath lung and successful development of targeted cancer therapies. The company's beta of -1.19 suggests a low correlation with the overall market, which could provide some downside protection in a market downturn. Investors should carefully weigh the potential rewards against the high risks associated with investing in a small biotechnology company with limited financial resources.

Based on FMP financials and quantitative analysis

BIAF Key Highlights

Market Cap of $3.93M reflects its status as a micro-cap company, indicating high growth potential but also significant risk.

• Gross Margin of 22.1% demonstrates some ability to generate profit from its sales, but this needs to be improved to achieve profitability.
• Profit Margin of -280.6% indicates significant losses, requiring careful monitoring of cash flow and funding requirements.
• Beta of -1.19 suggests the stock is less volatile than the market, but this may also limit upside potential.
• Focus on CyPath lung diagnostic test for early lung cancer detection addresses a critical unmet need in healthcare.

Who Are BIAF's Competitors?

BIAF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BIAF's Key Strengths?

Innovative CyPath lung diagnostic test.

• Focus on early lung cancer detection.
• Research and development capabilities in targeted cancer therapies.
• Experienced management team.

What Are BIAF's Weaknesses?

Limited financial resources.

• Negative profit margin.
• Small market capitalization.
• Reliance on a single product (CyPath lung).

What Could Drive BIAF Stock Higher?

Potential FDA approval for CyPath lung diagnostic test.

• Expansion of CyPath lung's market reach through strategic partnerships.
• Development and commercialization of new targeted cancer therapies.
• Positive clinical trial results for CyPath lung and other diagnostic tests.

What Are the Key Risks for BIAF?

Financial-distress signal — its Altman Z-Score of -18.79 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from larger, more established companies in the diagnostics market.
• Regulatory hurdles and delays in obtaining FDA approval.
• Limited financial resources and need for additional funding.
• Technological obsolescence and the emergence of new diagnostic technologies.
• Negative profit margin and the need to achieve profitability.

What Are the Growth Opportunities for BIAF?

• Expansion of CyPath lung's Market Reach: bioAffinity Technologies has the opportunity to expand the market reach of its CyPath lung diagnostic test by targeting additional healthcare providers and geographic regions. The market for early lung cancer detection is estimated to be substantial, with a growing demand for non-invasive diagnostic tools. Successful expansion could significantly increase revenue and market share, with a potential timeline of 2-3 years.
• Development of Targeted Cancer Therapies: The company's research into targeted cancer therapies represents a significant growth opportunity. By developing innovative treatments that address cancer at the cellular level, bioAffinity Technologies could capture a share of the rapidly growing market for personalized medicine. The timeline for developing and commercializing new therapies is typically longer, potentially 5-7 years, but the potential rewards are substantial.
• Strategic Partnerships and Collaborations: bioAffinity Technologies can pursue strategic partnerships and collaborations with other companies in the healthcare industry to accelerate its growth. Collaborations with pharmaceutical companies, research institutions, or diagnostic testing providers could provide access to new markets, technologies, and funding sources. These partnerships could be established within the next 1-2 years.
• FDA Approval and Regulatory Milestones: Achieving FDA approval for CyPath lung and other diagnostic tests is a critical growth driver for bioAffinity Technologies. FDA approval would validate the safety and efficacy of its products, opening up new market opportunities and enhancing its credibility with healthcare providers. The timeline for FDA approval can vary, but typically takes 1-3 years.
• Geographic Expansion into International Markets: bioAffinity Technologies can expand its operations into international markets to tap into new sources of revenue and growth. The global market for cancer diagnostics and therapeutics is substantial, with significant opportunities in Europe, Asia, and other regions. International expansion could be pursued within the next 3-5 years.

What Are BIAF's Competitive Advantages?

• Proprietary CyPath lung diagnostic technology.
• Focus on non-invasive early cancer detection.
• Research and development expertise in targeted cancer therapies.
• Potential for strong intellectual property protection through patents and trademarks.

What Does BIAF Do?

Founded in 2014 and based in San Antonio, Texas, bioAffinity Technologies, Inc. is a biotechnology company dedicated to developing innovative diagnostic tests and targeted cancer therapeutics. The company's primary focus is on early cancer detection and treatment at the cellular level. Its flagship product, CyPath lung, is a non-invasive diagnostic test designed for the early detection of lung cancer. This test aims to improve patient outcomes by enabling earlier diagnosis and treatment interventions. bioAffinity Technologies is committed to researching and developing targeted therapies that address cancer at its fundamental biological mechanisms. The company's research efforts are geared towards creating treatments that are more effective and less toxic than traditional cancer therapies. By focusing on targeted approaches, bioAffinity Technologies seeks to minimize side effects and improve the quality of life for cancer patients. Since its inception, bioAffinity Technologies has been dedicated to advancing the field of cancer diagnostics and therapeutics. The company's strategic focus on non-invasive diagnostic tools and targeted therapies positions it as a key player in the evolving landscape of personalized medicine. With a team of 57 employees, bioAffinity Technologies continues to innovate and expand its offerings to meet the growing needs of the healthcare industry.

What Products and Services Does BIAF Offer?

• Develop non-invasive diagnostic tests for early cancer detection.
• Offer CyPath lung, a diagnostic test for early detection of lung cancer.
• Research targeted therapies to treat cancer at the cellular level.
• Focus on improving patient outcomes through early diagnosis and treatment.
• Innovate in the field of personalized medicine.
• Provide diagnostic solutions for healthcare providers.

How Does BIAF Make Money?

• Generate revenue through the sale of CyPath lung diagnostic tests.
• License its diagnostic technologies to other companies.
• Receive research grants and funding from government agencies and private organizations.
• Potentially generate revenue from future sales of targeted cancer therapeutics.

What Industry Does BIAF Operate In?

bioAffinity Technologies operates within the medical diagnostics and research industry, a sector characterized by rapid innovation and intense competition. The market for cancer diagnostics is experiencing significant growth, driven by increasing cancer incidence and advancements in diagnostic technologies. The company competes with larger, more established players in the diagnostics market. bioAffinity Technologies' focus on non-invasive diagnostics and targeted therapies positions it within a niche segment of the industry, offering potential for differentiation and growth. The industry is subject to stringent regulatory requirements, requiring companies to navigate complex approval processes.

Who Are BIAF's Key Customers?

• Healthcare providers, including hospitals and clinics.
• Oncologists and pulmonologists.
• Patients at risk of or suspected of having lung cancer.
• Research institutions and pharmaceutical companies (for potential collaborations).

The most recent 9 insider filings for bioAffinity Technologies, Inc. break down as 0 sales and 9 purchases. On net that is roughly 290K shares acquired (about $0) — insiders putting money in tends to read as conviction.

Wall Street analysts project bioAffinity Technologies, Inc. revenue of about $7.3M for fiscal 2026, with EPS near $-121.50.

bioAffinity Technologies, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1.0% below estimates on average.

bioAffinity Technologies, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -18.79 places it in the distress zone, a signal of elevated financial risk.

bioAffinity Technologies, Inc. (BIAF) Valuation Context

Valued at $3.93M, BIAF is classified as a micro-cap stock. Relative to its peer group, BIAF's quantitative score of 18/100 is below the peer average of 55/100.

BIAF Revenue & Earnings Trend

In Jun 2026, BIAF generated $1.5M in top-line revenue, marking a sequential increase of 11.8%. The company recorded a net loss of $3.4M, with diluted EPS of $-9.66. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BIAF averaged $-30.04 in diluted EPS.

Company Profile

bioAffinity Technologies, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in San Antonio, US. The company is led by CEO Maria Zannes. BIAF has traded publicly since 2022.

BIAF Financials

BIAF Latest News

BIAF Analyst Consensus

BIAF MoonshotScore

BIAF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources